Псориаз и психиатрическая коморбидность


DOI: https://dx.doi.org/10.18565/pharmateca.2019.8.8-12

Л.С. Круглова (1), А.В. Пушкина (1), А.А. Хотко (2)

1) Центральная государственная медицинская академия, Москва, Россия; 2) Клинический кожно-венерологический диспансер, Краснодар, Россия
Данная статья носит обзорный характер. Псориаз является хроническим заболеванием, влияющим на качество жизни пациен-
тов. Это заболевание связано с повышенным риском возникновения коморбидных психических расстройств, которые могут быть не полностью распознаны врачом-дерматовенерологом в рамках амбулаторного приема. Крайне важно понять влияние этого заболевания на психическое здоровье и определить факторы риска, которые могут помочь в выявлении пациентов, подверженных психическим заболеваниям. Выявляя пациентов с псориазом высокого риска развития психиатрической патологии, дерматологи могут стремиться к оптимальному междисциплинарному лечению заболевания и таким образом помочь облегчить связанную с ним психиатрическую симптоматику.
Ключевые слова: псориаз, качество жизни, психические расстройства, психические заболевания, коморбидность

Литература


1. Menter A., Gottlieb A., Feldman S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50. Doi: 10.1016/j.jaad.2008.02.039.


2. Kumar S., Kachhawha D., Das Koolwal G., et al. Psychiatric morbidity in psoriasis patients: a pilot study. Indian J Dermatol Venereol Leprol. 2011;77:625. Doi: 10.4103/0378-6323.84074.


3. Kimball A.B., Guérin A., Tsaneva M., et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157–63. Doi: 10.1111/j.1468-3083.2010.03730.x.


4. Daudén E., Puig L., Ferrándiz C., et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2016;30(2):1–18. Doi: 10.1111/jdv.13542.


5. Palijan T.Z., Kovacevic D., Koic E., et al. The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis. Coll Antropol. 2011;35(2):81–5.


6. Richards H.L., Fortune D.G., Griffiths C.E., Main C.J. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001;50(1):11–5. Doi: 10.1016/s0022-3999(00)00210-5.


7. Evers A.W., Verhoeven E.W., Kraaimaat F.W., et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol. 2010;163:986–91. Doi: 10.1111/j.1365-2133.2010.09984.x.


8. Moynihan J., Rieder E., Tausk F. Psychoneuroimmunology: the example of psoriasis. G Ital Dermatol Venereol. 2010;145:221–28.


9. Hunter H.J., Griffiths C.E., Kleyn C.E. Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol. 2013;169:965–74. Doi: 10.1111/bjd.12478.


10. Reich A., Hrehorów E., Szepietowski J.C. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol. 2010;90:257–63. Doi: 10.2340/00015555-0851.


11. Heller M.M., Lee E.S., Koo J.Y. Stress as an influencing factor in psoriasis. Skin Therapy Lett. 2011;16:1–4.


12. Jankovic S., Raznatović M., Marinkovic J., et al. Relevance of psychosomatic factors in psoriasis: a case-control study. Acta Derm Venereol. 2009;89:364–68. Doi: 10.2340/00015555-0669


13. Dowlatshahi E.A., Wakkee M., Arends L.R., Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542–51. Doi: 10.1038/jid.2013.508.


14. Olfson M., Marcus S.C., Druss B., et al. National trends in the outpatient treatment of depression. JAMA. 2002;287(2):203–9. Doi: 10.1001/jama.287.2.203.


15. Esposito M., Saraceno R., Giunta A., et al. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123–27. Doi: 10.1159/000090652.


16. Schmitt J.M., Ford D.E. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215(1):17–27. Doi: 10.1159/000102029.


17. Fleming P., Roubille C., Richer V., et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(6):1063–70. Doi: 10.1111/jdv.12909.


18. Kurd S.K., Troxel A.B., Crits-Christoph P., Gelfand J.M.The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–95. Doi: 10.1001/archdermatol.2010.186.


19. Gupta M.A., Gupta A.K. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4:833–42. Doi: 10.2165/00128071-200304120-00003.


20. Bouguéon K., Misery L. Depression and psoriasis. Ann Dermatol Venereol. 2008;135(4):254–58. Doi: 10.1016/S0151-9638(08)70544-1.


21. Martín B., Sánchez-Carazo J.L., Pérez-Ferriols A.,et al. Clinical experience with etanercept in the treatment of psoriasis. Actas Dermosifiliogr. 2008;99:540–45.


22. Rieder E., Tausk F. Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatments. Int J Dermatol. 2012;51:12–26. Doi: 10.1111/j.1365-4632.2011.05071.x.


23. Gowda S., Goldblum O.M., McCall W.V., Feldman S.R.Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010;63:114–23. Doi: 10.1016/j.jaad.2009.07.003.


24. Kannan S., Heller M.M., Lee E.S., Koo J.Y. The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know. J Dermatolog Treat. 2013;24:148–52. Doi: 10.3109/09546634.2011.619159.


25. Hagforsen E., Michaëlsson K., Lundgren E., et al. Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: a case-control study. Acta Derm Venereol. 2005;85:225–32. Doi: 10.1080/00015550510026587.


26. Sandyk R., Pardeshi R. Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin. Int J Neurosci. 1990;50:215–21.


27. Devrimci-Ozguven H., Kundakci T.N., Kumbasar H., et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14:267–71. Doi: 10.1046/j.1468-3083.2000.00085.x.


28. Kaufman K.R. Etanercept, anticytokines and mania. Int Clin Psychopharmacol. 2005;20:239–41. Doi: 10.1097/00004850-200507000-00008


29. Demirhan O., Demirbek B., Tunc E., et al. Identification of chromosome abnormalities in screening of a family with manic depression and psoriasis: predisposition to aneuploidy. Asian J Psychiatr. 2012;5:169–74. Doi: 10.1016/j.ajp.2012.02.005.


30. Basavaraj K.H., Navya M.A., Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011;50:783–92. Doi: 10.1111/j.1365-4632.2010.04844.x.


31. Crosta M.L., Caldarola G., Fraietta S., et al. Psychopathology and eating disorders in patients with psoriasis. G Ital Dermatol Venereol. 2014;149:355–61.


32. Rubino I.A., Zanna V. Further comments on psoriasis and personality disorders. Psychol Rep. 1996;79(3 Pt 2):1248–50.


33. Kotrulja L., Tadinac M., Joki-Begi N.A., Gregurek R.A multivariate analysis of clinical severity, psychological distress and psychopathological traits in psoriatic patients. Acta Derm Venereol. 2010;90:251–56. Doi: 10.2340/00015555-0838.


34. Yang Y.W., Lin H.C. Increased risk of psoriasis among patients with schizophrenia: a nationwide population-based study. Br J Dermatol. 2012;166:899–900. Doi: 10.1111/j.1365-2133.2011.10684.x.


35. Miyaoka T., Seno H., Inagaki T., et al. Schizophrenia associated with psoriasis vulgaris: three case reports. Schizophr Res. 2000;41:383–86.


36. Latini A., Carducci M. Psoriasis during therapy with olanzapine. Eur J Dermatol. 2003;13:404–5.


37. Ascari-Raccagni A., Baldari U., Rossi E., Alessandrini F. Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy. J Eur Acad Dermatol Venereol. 2000;14:315–16. Doi: 10.1046/j.1468-3083.2000.00056-3.x


38. Di Nuzzo S., Zanni M., De Panfilis G. Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A but not with etanercept. J Drugs Dermatol. 2007;6:1046–47.


39. Callis Duffin K., Wong B., Horn E.J., Krueger G.G. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol. 2009;60:604–8. Doi: 10.1016/j.jaad.2008.10.059.


40. Shutty B.G., West C., Huang K.E., et al. Sleep disturbances in psoriasis. Dermatol Online J. 2013;19:1.


41. Picardi A., Pasquini P., Cattaruzza M.S., et al. Only limited support for a role of psychosomatic factors in psoriasis. Results from a case-control study. J Psychosom Res. 2003;55:189–96. Doi: 10.1016/s0022-3999(02)00574-3


42. Poikolainen K., Reunala T., Karvonen J., et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ. 1990;300:780–783. Doi: 10.1136/bmj.300.6727.780.


43. Bahmer J.A., Kuhl J., Bahmer F.A. How do personality systems interact in patients with psoriasis, atopic dermatitis and urticaria? Acta Derm Venereol. 2007;87:317–24. Doi: 10.2340/00015555-0246.


44. Meyer N., Viraben R., Paul C. Addictions and psoriasis: an example of the dermatologist’s implication in preventive medicine? Ann Dermatol Venereol. 2008;135(4):259–62. Doi: 10.1016/S0151-9638(08)70545-3.


45. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61–7. Doi: 10.1111/j.0022-202X.2005.23681.x.


46. Adamzik K., McAleer M.A., Kirby B. Alcohol and psoriasis: sobering thoughts. Clin Exp Dermatol. 2013;38:819–22. Doi: 10.1111/ced.12013.


47. Dediol I., Buljan M., Buljan D., et al. Association of psoriasis and alcoholism: psychodermatological issue. Psychiatr Danub. 2009;21:9–13.


Об авторах / Для корреспонденции


Автор для связи: А.В. Пушкина, аспирант кафедры дерматовенерологии и косметологии, Центральная государственная медицинская академия, Москва, Россия; e-mail: anyasawina@gmail.com
Адрес: 121359, Россия, Москва, ул. Маршала Тимошенко, 19, стр. 1А


ORCID / eLibrary SPIN:
Л.С. Круглова https://orcid.org/0000-0002-5044-5265; eLibrary SPIN: 1107-4372
А.В. Пушкина https://orcid.org/0000-0002-2742-436X; eLibrary SPIN: 4129-7003
А.А. Хотко https://orcid.org/0000-0002-8688-4876; eLibrary SPIN: 6929-3790


Бионика Медиа